636 related articles for article (PubMed ID: 29678413)
1. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
2. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
3. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
4. Access to medicines - a systematic review of the literature.
Abbas N; Hasan SS; Curley L; Babar ZU
Res Social Adm Pharm; 2020 Sep; 16(9):1166-1176. PubMed ID: 31839584
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea.
Hasan SS; Kow CS; Dawoud D; Mohamed O; Baines D; Babar ZU
Value Health Reg Issues; 2019 May; 18():18-23. PubMed ID: 30414506
[TBL] [Abstract][Full Text] [Related]
6. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
7. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
9. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
Maniadakis N; Kourlaba G; Shen J; Holtorf A
BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
[TBL] [Abstract][Full Text] [Related]
11. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
12. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
13. The relevance of systematic reviews on pharmaceutical policy to low- and middle-income countries.
Gray AL; Suleman F
Int J Clin Pharm; 2015 Oct; 37(5):717-25. PubMed ID: 26177819
[TBL] [Abstract][Full Text] [Related]
14. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
15. Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.
Ocran Mattila P; Ahmad R; Hasan SS; Babar ZU
Front Public Health; 2021; 9():628744. PubMed ID: 33996712
[No Abstract] [Full Text] [Related]
16. Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study.
Grover P; Babar ZU; Oehmen R; Vitry A
Health Policy; 2018 Mar; 122(3):243-249. PubMed ID: 29295745
[TBL] [Abstract][Full Text] [Related]
17. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
18. A review of promoting access to medicines in China - problems and recommendations.
Sun J; Hu CJ; Stuntz M; Hogerzeil H; Liu Y
BMC Health Serv Res; 2018 Feb; 18(1):125. PubMed ID: 29458428
[TBL] [Abstract][Full Text] [Related]
19. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
20. Widening consumer access to medicines: a comparison of prescription to non-prescription medicine switch in Australia and New Zealand.
Gauld NJ; Kelly FS; Emmerton LM; Buetow SA
PLoS One; 2015; 10(3):e0119011. PubMed ID: 25785589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
